Study Design Segment Analysis: Interventional Studies (Largest Segment) vs Expanded Access Studies (Fastest-Growing Segment)

The interventional studies segment held the largest share of the HIV clinical trials market, accounting for 67.71% in 2026, supported by its central role in evaluating the safety, efficacy, dosing, and therapeutic performance of investigational HIV treatments under controlled clinical conditions. Interventional trials remain essential for generating evidence required to establish whether new therapies can achieve meaningful clinical outcomes and address persistent challenges such as viral suppression, treatment resistance, and long-term disease management. Continued development of innovative antiretroviral approaches and efforts to improve treatment outcomes are sustaining demand for structured clinical investigations. In addition, the need to evaluate novel therapeutic combinations and interventions across diverse patient populations reinforces the importance of interventional study designs. Their ability to generate systematic clinical evidence makes this segment a fundamental part of HIV drug development and contributes to its leading position.

Expanded access studies are expected to register the fastest growth, driven by increasing emphasis on making potentially beneficial investigational therapies available to patients who have limited or no satisfactory treatment alternatives. These studies can provide an important pathway for individuals with serious or advanced HIV disease to access emerging therapies while additional clinical evidence is being generated. The growing focus on patient-centered drug development and broader access to innovative treatments is increasing the relevance of expanded access programs within the clinical research ecosystem. Such studies can also generate valuable real-world information regarding treatment tolerability and therapeutic use outside conventional trial settings. As researchers, healthcare providers, and regulatory stakeholders place greater emphasis on timely access to promising HIV therapies, expanded access studies are gaining importance as a complementary mechanism within clinical development.

Phase Segment Analysis: Phase III (Largest Segment) vs Phase I (Fastest-Growing Segment)

Phase III trials represented the largest segment of the HIV clinical trials market, holding 32.4% share in 2026, reflecting their critical importance in confirming the efficacy and safety of therapies before broader regulatory adoption. These large-scale studies provide comprehensive evidence regarding treatment performance across diverse patient populations and are essential for assessing the benefits and risks of candidate therapies under conditions that more closely reflect routine clinical use. The continued development of improved HIV treatments, combination regimens, and therapies designed to address treatment resistance supports the need for advanced-stage clinical evaluation. Phase III investigations also play an important role in generating the evidence needed to establish clinical value and inform treatment guidelines. Their strategic position within the drug development pathway therefore sustains substantial activity in this segment.

Phase I is anticipated to experience the fastest growth as pharmaceutical and biotechnology developers increasingly explore novel approaches to HIV treatment and prevention. Early-stage trials are essential for establishing initial safety, tolerability, pharmacokinetic characteristics, and appropriate dosing strategies before therapies progress into larger investigations. Innovation in therapeutic mechanisms is creating a broader pipeline of candidates that require first-in-human evaluation, increasing the importance of phase I research. The growing focus on developing treatments that can address viral persistence, resistance, and limitations associated with existing therapies is also encouraging earlier-stage investigation of differentiated candidates. As the HIV research pipeline continues to pursue new therapeutic concepts, phase I studies are becoming increasingly important for determining which emerging candidates can advance through the clinical development process.